8-KMaterial AgreementsExhibits & Filings

AMGEN INC 8-K Report, Material Agreement (Nov 2, 2007)

Filed November 2, 2007For Securities:AMGN

Summary

This Form 8-K filing by Amgen Inc. (AMGN) on November 2, 2007, primarily announces the execution of a new, significant revolving credit agreement, replacing a prior facility. This new agreement provides Amgen with a substantial $2.5 billion in available financing, with an option to increase it by an additional $500 million. The funds are designated for general corporate purposes, including support for commercial paper. Investors should note the increased borrowing capacity, which offers enhanced financial flexibility for Amgen's operations, potential acquisitions, or strategic investments. The agreement's five-year initial term, extendable for two additional one-year periods, indicates a medium-term commitment from the lending syndicate. The terms related to interest rates (LIBOR or base rate plus a spread) and commitment fees are tied to Amgen's debt rating and utilization, suggesting a cost of capital that will fluctuate with the company's financial health and leverage.

Key Highlights

  • 1Amgen entered into a new revolving credit agreement worth $2.5 billion, replacing a previous $1.0 billion facility.
  • 2The new credit facility provides increased financial flexibility for general corporate purposes, including commercial paper support.
  • 3The agreement includes an option to increase the total commitment by an additional $500 million.
  • 4The initial term of the credit facility is five years, with potential extensions for up to two additional one-year periods.
  • 5Interest rates are variable, based on either the LIBOR rate or a base commercial lending rate, plus a spread dependent on utilization and debt rating.
  • 6Amgen will pay a commitment fee on both used and unused portions of the credit line, also influenced by its debt rating.
  • 7The agreement features a $300 million sub-limit specifically for the issuance of letters of credit.

Frequently Asked Questions

The main purpose of this 8-K filing is to announce Amgen's entry into a new, larger revolving credit agreement valued at $2.5 billion, which replaces its previous $1.0 billion credit facility.

The new agreement significantly increases Amgen's available financing by $1.5 billion, providing greater financial flexibility for general corporate purposes, such as supporting commercial paper issuances, operational needs, or strategic initiatives. The increased capacity and potential for further expansion offer enhanced financial stability.

The agreement has an initial term of five years, extendable by up to two one-year periods. Interest rates are variable, tied to LIBOR or a base rate plus a spread determined by Amgen's debt rating and facility utilization. A commitment fee is also payable on the committed amount. Additionally, there's a $300 million sub-limit for letters of credit.

The interest rate and fee structure are linked to Amgen's long-term unsecured debt rating and its utilization of the credit facility. This means that as Amgen's creditworthiness improves (higher rating) or its borrowing decreases, the cost of this financing may become more favorable, reflecting a dynamic relationship between the company's financial health and its borrowing costs.